Articles From: AMETEK Announces Record Third Quarter Results to Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans


BERWYN, Pa.
Sign-up for AMETEK Announces Record Third Quarter Results investment picks
BERWYN, Pa.
Sign-up for AMETEK Announces Two Executive Appointments investment picks
BERWYN, Pa.
Sign-up for AMETEK Declares Quarterly Dividend of Nine Cents Per Share investment picks
BERWYN, Pa.
Sign-up for AMETEK Increases Share Repurchase Authorization investment picks
PRESENTATION TO BE WEBCAST AT 3:00 PM CT ON TUESDAY, NOVEMBER 11TH BERWYN, Pa.
Sign-up for AMETEK to Present at Baird's 2014 Industrial Conference investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) today announced that Dr.
Sign-up for AMG Announces Retirement of Rita M. Rodriguez from its Board of Directors investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) today announced the completion of its additional investment in AQR Capital Management, LLC, a leading global investment manager.
Sign-up for AMG Completes Investment in AQR Capital Management investment picks
Affiliated Managers Group, Inc. (NYSE: AMG), a global asset management company, today announced the completion of its investment in Veritas Asset Management LLP (“Veritas”). Founded in 2003, Veritas is a leading independent global and Asian equity manager with award-winning investment strategies that seek to deliver long-term real returns through both long-only and long-short mandates across both funds and segregated portfolios.
Sign-up for AMG Completes Investment in Veritas Asset Management investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) today announced it has agreed to a transaction which will result in a meaningful increase in its minority investment in AQR Capital Management, LLC, a leading global investment manager and an AMG Affiliate since 2004.
Sign-up for AMG Increases its Investment in AQR Capital Management investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) today reported its financial and operating results for the third quarter and nine months ended September 30, 2014.
Sign-up for AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2014 investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the fourth quarter and full year ended December 31, 2014 on Tuesday, January 27, 2015.
Sign-up for AMG to Announce Fourth Quarter and Full Year Results on January 27, 2015 investment picks
Affiliated Managers Group, Inc. (NYSE: AMG) will report financial and operating results for the third quarter ended September 30, 2014 on Monday, November 3, 2014.
Sign-up for AMG to Announce Third Quarter Results on November 3, 2014 investment picks
Brodalumab Meets All Primary and All Key Secondary Endpoints Meets Primary Endpoint of Superiority to Stelara® (ustekinumab) in Achieving Total Skin Clearance (PASI 100) Meets Co-Primary Endpoints Against Placebo THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
Study Met All Primary Endpoints Against Stelara® (ustekinumab) and Placebo Three Pivotal Studies Form the Basis for Global Regulatory Filings, Planned In 2015 THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
First Presentation of Phase 3 Data From Brodalumab Psoriasis Program THOUSAND OAKS, Calif.
Sign-up for Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
Alliance Combines Amgen's Oncology Targets and Kite's Leading CAR T Cell Therapy Platform to Develop new Therapeutic Candidates Kite to Receive a $60 Million Upfront Payment From Amgen and Eligible for up to $525 Million in Regulatory and Sales Milestone Payments per Amgen Program; Plus, Tiered High Single- to Double-Digit Royalties for Sales and License of Kite's Intellectual Property for CAR T Cell Products Amgen Eligible to Receive up to $525 Million in Milestone Payments per Kite Program; Plus, Tiered Single-Digit Sales Royalties Kite to Host Conference Call Today at 4:00 PM Eastern Time THOUSAND OAKS, Calif.
Sign-up for Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies investment picks
By Tess Stynes Amgen Inc. and Kite Pharma Inc. reached a research collaboration and license agreement to develop cancer immunotherapy treatments that focus on Amgen's array of cancer targets and Kite Pharma's autologous cell therapy platform.
Sign-up for Amgen and Kite Pharma in cancer immunotherapy pact investment picks
MD Anderson's Moon Shots Program key to Collaboration THOUSAND OAKS, Calif.
Sign-up for Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome investment picks
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition Overall Response Rate, Duration of Response, Health-Related Quality of Life Secondary Endpoints Met; Overall Survival Continues to be Monitored Results to be Presented During an Oral Session at ASH on Sunday, December 7 at 12 p.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 8 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend investment picks
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle Results to be Presented During an Oral Session at the American Society of Hematology (ASH) 56th Annual Meeting and Exposition on Monday, December 8 at 10:30 a.m. PT Data to be Featured in ASH Press Briefing on Saturday, December 6 at 10 a.m. PT THOUSAND OAKS, Calif.
Sign-up for Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease investment picks
Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer investment picks
THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Webcast of 2014 Third Quarter Financial Results investment picks
2014/11/24
By Tess Stynes Amgen Inc. said it ended clinical studies of a treatment for advanced stomach cancer based on safety concerns.
Sign-up for Amgen ends trials of stomach-cancer therapy investment picks
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND OAKS, Calif.
Sign-up for Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 investment picks
Sponsorship Secures Resources Needed for Biotech Startups to Advance Innovative Research CAMBRIDGE, Mass.
Sign-up for Amgen Joins With LabCentral To Support Life-Sciences And Biotech Startups In Cambridge, Massachusetts investment picks
Amgen Inc. (AMGN) said late Monday that third-quarter net income was $1.24 billion, or $1.61 a share, compared with $1.37 billion, or $1.79 a share, for the same period a year ago.
Sign-up for Amgen net drops, but adjusted earnings beat views investment picks
Plans to Payout Approximately 60 Percent of Adjusted Net Income on Average to Shareholders Through 2018 Guides to Improved Adjusted Operating Margin of 52-54 Percent by 2018 Reinitiating Share Repurchases With Plans for Approximately $2 Billion Through 2015 Plans to Increase Dividend 30 Percent Beginning 1Q 2015 Expects to Deliver Double-Digit Adjusted Earnings Per Share (EPS) Growth on Average Through 2018 $1.5 Billion in Annual Savings Planned by 2018 Preparing to Launch Four High-Potential Innovative Medicines in 2015 Expands Biosimilars Portfolio to Nine Programs, Total Portfolio Represents a $3 Billion Plus Opportunity Launching Next-Generation Biomanufacturing Technologies in 2017 Provides Preliminary 2015 Guidance of Revenues of $20.8-$21.3 Billion and Adjusted EPS of $9.05-$9.40 NEW YORK , Oct.
Sign-up for Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: AMETEK Announces Record Third Quarter Results to Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent